X0609 4 2026-09-24 0001645469 Monopar Therapeutics MNPR 0001727334 Robinson Chandler false 1000 SKOKIE BLVD SUITE 350 WILMETTE IL 60091 1 1 Chief Executive Officer 1 Common Stock 2026-09-24 4 M 0 14056 30 A 113323 D Common Stock 2026-09-24 4 M 0 15000 14 A 128323 D Common Stock 2026-09-24 4 S 0 10450 87.15 D 117873 D Common Stock 2026-09-24 4 S 0 9638 87.96 D 108235 D Common Stock 2026-09-24 4 S 0 8368 88.97 D 99867 D Common Stock 2026-09-24 4 S 0 600 89.79 D 99267 D Common Stock 62815 I See Footnote Stock Option 30 2026-09-24 4 M 0 14056 0 D 2028-08-08 Common Stock 14056 15044 D Stock Option 14 2026-09-24 4 M 0 15000 0 D 2032-02-01 Common Stock 15000 27204 D This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026. On August 9, 2018, the reporting person was granted stock options to purchase up to 29,100 shares of common stock. Stock options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter. On February 2, 2022, the reporting person was granted stock options to purchase up to 42,204 shares of common stock. Stock options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter. Represents shares held by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.54 to $87.53, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.54 to $88.53, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.54 to $89.51, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.56 to $89.91, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4. /s/ Quan Vu, Attorney-in-fact 2026-09-28